诱导多能干细胞
组织工程
药物发现
干细胞
再生医学
间质细胞
间充质干细胞
药物开发
医学
神经科学
生物医学工程
药品
计算生物学
药理学
生物
细胞生物学
生物信息学
癌症研究
病理
胚胎干细胞
基因
生物化学
作者
Evangeline Tzatzalos,Oscar J. Abilez,Praveen Shukla,Joseph C. Wu
标识
DOI:10.1016/j.addr.2015.09.010
摘要
Engineered heart tissue has emerged as a personalized platform for drug screening. With the advent of induced pluripotent stem cell (iPSC) technology, patient-specific stem cells can be developed and expanded into an indefinite source of cells. Subsequent developments in cardiovascular biology have led to efficient differentiation of cardiomyocytes, the force-producing cells of the heart. iPSC-derived cardiomyocytes (iPSC-CMs) have provided potentially limitless quantities of well-characterized, healthy, and disease-specific CMs, which in turn has enabled and driven the generation and scale-up of human physiological and disease-relevant engineered heart tissues. The combined technologies of engineered heart tissue and iPSC-CMs are being used to study diseases and to test drugs, and in the process, have advanced the field of cardiovascular tissue engineering into the field of precision medicine. In this review, we will discuss current developments in engineered heart tissue, including iPSC-CMs as a novel cell source. We examine new research directions that have improved the function of engineered heart tissue by using mechanical or electrical conditioning or the incorporation of non-cardiomyocyte stromal cells. Finally, we discuss how engineered heart tissue can evolve into a powerful tool for therapeutic drug testing.
科研通智能强力驱动
Strongly Powered by AbleSci AI